WO2009043987A9 - Compositions antibiotiques a base d'huiles essentielles - prophylaxie et traitement d'infections nosocomiales - Google Patents

Compositions antibiotiques a base d'huiles essentielles - prophylaxie et traitement d'infections nosocomiales Download PDF

Info

Publication number
WO2009043987A9
WO2009043987A9 PCT/FR2008/001012 FR2008001012W WO2009043987A9 WO 2009043987 A9 WO2009043987 A9 WO 2009043987A9 FR 2008001012 W FR2008001012 W FR 2008001012W WO 2009043987 A9 WO2009043987 A9 WO 2009043987A9
Authority
WO
WIPO (PCT)
Prior art keywords
prophylaxis
treatment
containing essential
compositions containing
essential oils
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2008/001012
Other languages
English (en)
Other versions
WO2009043987A1 (fr
Inventor
Elisabeth Marie-Ange Yvette Rossines
Gérard Panhelleux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aroma Technologies SAS
Original Assignee
Aroma Technologies SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aroma Technologies SAS filed Critical Aroma Technologies SAS
Priority to EP08834729A priority Critical patent/EP2175870A1/fr
Publication of WO2009043987A1 publication Critical patent/WO2009043987A1/fr
Publication of WO2009043987A9 publication Critical patent/WO2009043987A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention objet de la présente demande concerne une nouvelle composition antibiotique, de nouvelles associations médicamenteuses et de nouvelles formulations à base d'huile(s) essentielle(s), ainsi que leur utilisation pour la prophylaxie et/ou le traitement d'infections en général et d'infections bactériennes nosocomiales en particulier. L'invention a également pour objet une méthode pour diminuer le nombre de bactéries présentes sur une surface. L'invention a également pour objet une méthode pour prévenir ou traiter une infection bactérienne, en particulier une infection nosocomiale, chez un mammifère en particulier chez un humain, ladite méthode comprenant (i) l'administration d'au moins un antibiotique et (ii) l'administration d'au moins une formulation d'huile(s) essentielle(s). Les composés (i) et (ii) peuvent être administrés simultanément (sous la forme d'un mélange ou, alternativement, sous la forme de formulations distinctes) et/ou séparément dans le temps.
PCT/FR2008/001012 2007-07-10 2008-07-10 Compositions antibiotiques a base d'huiles essentielles - prophylaxie et traitement d'infections nosocomiales Ceased WO2009043987A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08834729A EP2175870A1 (fr) 2007-07-10 2008-07-10 Compositions antibiotiques a base d'huiles essentielles - prophylaxie et traitement d'infections nosocomiales

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0704991 2007-07-10
FR0704991A FR2918571B1 (fr) 2007-07-10 2007-07-10 Compositions antibiotiques a base d'huiles essentielles prophylaxie et traitement d'infections nosocomiales

Publications (2)

Publication Number Publication Date
WO2009043987A1 WO2009043987A1 (fr) 2009-04-09
WO2009043987A9 true WO2009043987A9 (fr) 2009-10-01

Family

ID=39135270

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2008/001012 Ceased WO2009043987A1 (fr) 2007-07-10 2008-07-10 Compositions antibiotiques a base d'huiles essentielles - prophylaxie et traitement d'infections nosocomiales

Country Status (3)

Country Link
EP (1) EP2175870A1 (fr)
FR (1) FR2918571B1 (fr)
WO (1) WO2009043987A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2946255B1 (fr) * 2009-06-05 2013-05-24 Natepharm Composition comprenant du trans-cinnamaldehyde
IT1401202B1 (it) * 2010-07-26 2013-07-12 Ist Superiore Sanita Uso del terpinen-4-ol come agente antimicrobico contro la legionella pneumophila.
CA2827239A1 (fr) 2011-02-25 2012-08-30 Universite D'angers Nanoencapsulation d'huiles essentielles pour la prevention et la guerison des maladies infectieuses seules ou associees a un antibiotique
FR3021218A1 (fr) * 2014-05-26 2015-11-27 Eydo Pharma Utilisation du cinnamaldehyde en association avec de l'eugenol et/ou du carvacrol pour lutter contre la resistance aux antibiotiques
FR3048612B1 (fr) 2016-03-14 2020-10-02 Septeos Tulathromycine potentialisee
GB201904963D0 (en) * 2019-04-08 2019-05-22 Anpario Plc Composition for reducing antimicrobial resistance
US12460153B2 (en) 2019-12-04 2025-11-04 Pranarom International S.A. Method for transforming an essential oil
US20230104874A1 (en) * 2020-10-16 2023-04-06 HerbElixa DOO BEOGRAD- NOVI BEOGRAD Herbal preparation for prevention and treatment of helicobacter pylori infection
CN112618486B (zh) * 2020-12-24 2023-07-18 浙江昂利康制药股份有限公司 一种注射用混悬油剂及其制备方法
FR3120187B1 (fr) * 2021-02-26 2023-12-01 Mathieu Angelidis Composition naturelle répulsive
CN113633614B (zh) * 2021-09-08 2023-04-07 中国人民解放军陆军军医大学 一种治疗难治性口腔溃疡的高效抗菌天然茶树精油纳米乳制剂及其制备方法和应用
CN113767937A (zh) * 2021-09-10 2021-12-10 江西中医药大学 复合精油组合物、制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1146111A1 (fr) * 2000-04-14 2001-10-17 The Procter & Gamble Company Procédé de désinfection des surfaces dures par utilisation d'une composition d'huile de cannelle et/ou ses constituants actifs
US6884763B2 (en) * 2001-10-30 2005-04-26 Permatex, Inc. Waterless hand cleaner containing plant derived natural essential oil
US20040071757A1 (en) * 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
WO2004045572A1 (fr) * 2002-11-21 2004-06-03 J.P.M.E.D. Ltd. Compositions servant a traiter la peau et la membrane muqueuse infectees et comprenant un agent anti-microbien et une huile essentielle
GB0405545D0 (en) * 2004-03-12 2004-04-21 Univ Manchester Antimicrobial composition
WO2006120494A1 (fr) * 2005-05-13 2006-11-16 Advanced Scientific Developements Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l’eugenol, le borneol et les carvacrol

Also Published As

Publication number Publication date
EP2175870A1 (fr) 2010-04-21
FR2918571A1 (fr) 2009-01-16
WO2009043987A1 (fr) 2009-04-09
FR2918571B1 (fr) 2013-01-11

Similar Documents

Publication Publication Date Title
WO2008092006A3 (fr) Compositions antimicrobiennes
BRPI1007379B8 (pt) composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
UA96964C2 (ru) Соединения полициклической мочевины с антибактериальными свойствами
NZ701559A (en) Compositions comprising povidone-iodine
WO2008020229A3 (fr) Composés chimiques
NO20092542L (no) Antibakterielle kinolin-derivater
TWI327573B (en) 6-11 bicyclic ketolide derivatives
NZ593831A (en) Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
BR112013011634A2 (pt) derivados de 2,3-di-hidroimidazol[1,2-c]quinazolina substituídos por aminoálcool úteis para tratar os distúrbios hiperproliferativos e as doenças associadas com a angiogênese derivados de 2,3-di-hidroimidazol[1,2-c]
WO2009128918A8 (fr) Polythérapie utilisant une hyaluronidase soluble et un bisphosphonate
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
FR2918571B1 (fr) Compositions antibiotiques a base d'huiles essentielles prophylaxie et traitement d'infections nosocomiales
DE60329098D1 (de) Verwendung von mastix und dessen ätherischen ölen zur verhinderung oder bekämpfung von mikrobieller infektionen
BRPI0405939A (pt) Formulações antibacterianas de uso tópico
WO2009019708A3 (fr) Compositions pharmaceutiques et procédés pour le traitement du cancer
MX2022011565A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
NO20092547L (no) Antibakterielle kinolin-derivater
WO2006063039A3 (fr) 3,6-bicyclolides
WO2006039263A3 (fr) Nouveaux derives 9a-azalidiques bicycliques
NO20092536L (no) Antibakterielle kinolin-derivater
NO20092540L (no) Antibakterielle kinolin-derivater
BR112023019720A2 (pt) Uso de análogos de rifamicina em combinação com vancomicina, composição farmacêutica compreendendo esses compostos, método in vitro para prevenir ou inibir o crescimento de uma bactéria e kit
WO2005067564A3 (fr) Derives d'erythromycine 6-11 bicyclique
NO20092541L (no) Antibakterielle kinolin-derivater

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08834729

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2008834729

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008834729

Country of ref document: EP